Currently, there are two main types of EGFR inhibitors: anti-EGFR monoclonal antibodies (mAbs) and small molecule tyrosine kinase inhibitors (TKIs), which have been widely used in the treatment of highly expressed EGFR tumors, including non-small-cell lung cancer, colon cancer, and pancreatic cancer [7–9]. This evidence concerns the gene EGFR and colonic neoplasm.